Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma
- PMID: 22906119
- PMCID: PMC3495889
- DOI: 10.1186/1477-7819-10-167
Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma
Abstract
We report two cases of gastrointestinal perforation (GIP) after radiotherapy in patients receiving tyrosine kinase inhibitor (TKI) for advanced renal cell carcinoma (RCC). Case 1 was a 61-year-old woman with lung metastases after a radical nephrectomy for a right RCC (cT3aN0M0) treated with interferon-alpha (OIF, 5 MIU, three times per week). She developed lytic metastases of the left femur and the left acetabulum. She was treated with palliative radiotherapy to the metastatic portion (3 Gy × 10 fractions), and 400 mg sorafenib twice per day plus continuing interferon alpha. She experienced sudden left lower abdominal pain after four weeks of treatment, and was diagnosed with a perforation of the sigmoid colon with fecal peritonitis. Case 2 was a 48-year-old man with lung, lymph node, and bone metastases after a radical nephrectomy for a right RCC (cT2N0M0), and was treated with 400 mg sorafenib twice per day. He developed lytic bone metastases of the lumbar vertebrae, which was treated with palliative radiotherapy to L2-4 (3 Gy × 10 fractions). He experienced sudden abdominal pain after two months of radiation treatment, and was diagnosed with a perforation of the sigmoid colon with fecal peritonitis. These cases underwent radiotherapy, and therefore this may be related to the radiosensitivity of TKI.
Figures



Similar articles
-
[Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].Nihon Hinyokika Gakkai Zasshi. 2012 Sep;103(5):660-4. doi: 10.5980/jpnjurol.103.660. Nihon Hinyokika Gakkai Zasshi. 2012. PMID: 23342925 Japanese.
-
Sorafenib induced eruptive melanocytic lesions.Dermatol Online J. 2013 May 15;19(5):18184. Dermatol Online J. 2013. PMID: 24011281
-
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.Urol Oncol. 2013 Nov;31(8):1800-5. doi: 10.1016/j.urolonc.2012.04.019. Epub 2012 May 31. Urol Oncol. 2013. PMID: 22658883 Clinical Trial.
-
[Myocardial metastasis from renal cell carcinoma treated with sorafenib].Hinyokika Kiyo. 2011 Oct;57(10):555-8. Hinyokika Kiyo. 2011. PMID: 22089153 Review. Japanese.
-
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.Int Urol Nephrol. 2013 Aug;45(4):1017-21. doi: 10.1007/s11255-013-0468-1. Epub 2013 May 18. Int Urol Nephrol. 2013. PMID: 23686671 Review.
Cited by
-
To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.World J Urol. 2014 Feb;32(1):59-67. doi: 10.1007/s00345-013-1068-5. Epub 2013 May 8. World J Urol. 2014. PMID: 23652926 Review.
-
Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature.J Gastrointest Cancer. 2016 Dec;47(4):420-422. doi: 10.1007/s12029-015-9752-x. J Gastrointest Cancer. 2016. PMID: 26223483 No abstract available.
-
Case report: Adjuvant therapy with toceranib for an incompletely resected renal cell carcinoma with suspected pulmonary metastasis in a dog.Front Vet Sci. 2023 Nov 13;10:1287185. doi: 10.3389/fvets.2023.1287185. eCollection 2023. Front Vet Sci. 2023. PMID: 38026615 Free PMC article.
-
Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients.Strahlenther Onkol. 2022 Sep;198(9):838-848. doi: 10.1007/s00066-022-01945-y. Epub 2022 Apr 26. Strahlenther Onkol. 2022. PMID: 35471558 Free PMC article.
-
Risk factors for severe gastrointestinal toxicity in patients receiving palliative radiotherapy for metastatic bone tumors: association with the use of molecular-targeted agents.J Radiat Res. 2020 Jul 6;61(4):629-634. doi: 10.1093/jrr/rraa035. J Radiat Res. 2020. PMID: 32567666 Free PMC article.
References
-
- Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. TARGET Study Group. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med. 2007;356:125–134. doi: 10.1056/NEJMoa060655. - DOI - PubMed
-
- Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338. doi: 10.1016/S0140-6736(06)69446-4. - DOI - PubMed
-
- The third interim analysis report (unresectable/metastatic renal cell carcinoma) of the postmarketing. 2011. Surveillance Review of Sorafenib.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical